An Act to Improve Patient Access to and Savings from Generic Dmgs and Biosimilars
Maine Legislature, Session 131, LD 2114
Committee Amendment CA_A_S651 (Senate)

COMMITTEE AMENDMENT "fr " to S.P. 907, L,D. 2114, "An Act to Improve
Patient Access to and Savings from Generic Dmgs and Biosimilars"
Amend the bill by striking out the title and substituting the following:
'Resolve, Directing the Superintendent of Insurance to Collect Data from Health
Insurers Related to Prescription Drug Coverage of Generic Drugs and Biosimilars'
Amend the bill by striking out everything aflter the title and inserting the following:
'See. 1. Superintendent of Insurance to collect data on prescription drug
coverage of generic drugs and biosimilars. Resolved: That the Superintendent of
Insurance shall request data from health insurance carriers that, at a minimum, provides
information related to each carrier's placement of generic drugs and biosimilars on the
carrier's prescription drug formulary, including whether a generic drug or biosimilar is
available on the carrier's fonnulary with a lower out-of-pocket cost to an enrollee than the
brand drug to which the generic drug or biosimilar is equivalent and whether the carrier
imposes any limitation on coverage of a generic drug or biosimilar or imposes a restriction
on a pharmacy that makes it more difficult for an enrollee to obtain coverage of or access
to a generic drug or biosimilar than the brand drug to which the generic drug or biosimilar
is equivalent. No later than February 15, 2025, the superintendent shall submit a report to
the joint standing committee of the Legislature having jurisdiction over health coverage,
insurance and fmancial services matters that summarizes the data submitted by the carriers
as requested, together with any fmdings or recommendations of the superintendent. The
joint standing committee may report out a bill to the 132nd Legislature m 2025 based on
the report.'
Amend the bill by relettering or renumbermg any nonconsecutive Part letter or section
number to read consecutively.
SUMMARY
This amendment replaces the bill with a resolve. The amendment directs the
Superintendent of Insurance to request data from health insurance carriers related to each
COMMITTEE AMENDMENT
COMMITTEE AMENDMENT " /^ " to S.P. 907, L.D. 2114 i Lr |
carrier's placement of generic drugs and biosimilars on the carrier's prescription drug
formulary, including whether a generic drug or biosimilar is available on the carrier's
formulary with a lower out-of-pocket cost to an enrollee than the brand drug to which the
generic dmg or biosimilar is equivalent and whether the carrier imposes any limitation on
coverage of a generic dmg or biosimilar or imposes a restriction on a pharmacy that makes
it more difficult for an enrollee to obtain coverage of or access to a generic drug or
biosimilar than the brand drug to which the generic dmg or biosimilar is equivalent. The
amendment requires the Superintendent of Insurance to report on the data submitted by the
carriers as requested, together with any findings or recommendations of the superintendent,
no later than February 15, 2025. The joint standing committee of the Legislature having
jurisdiction over health coverage, insurance and financial services matters may report out
a bill to the 132nd Legislature in 2025 based on the report,
FISCAL NOTE REQUIRED
(See attached)
Page2-131LR2790(02)
COMMITTEE AMENDMENT
Approved: 03/22/24 ^K^c--
LD 2114 LR 2790(02)
An Act to Improve Patient Access to and Savings from Generic Drugs and Biosimilars
Fiscal Note for Bill as Amended by Committee Amendment '^"/
Committee: Health Coverage, Insurance and Financial Services
Fiscal Note Required: Yes
Fiscal Note
Minor cost increase - Other Special Revenue Funds
Fiscal Detail and Notes
Any additional costs to the Department of Professional and Financial Regulation from the provisions of this bill are
expected to be minor and can be absorbed within existing budgeted resources.
LR2790(02) - Fiscal Note - Page 1 of 1